Evidence map›Paper›PMID 32309352›Full record

ArticleAnnals of translational medicine2020

Clinicopathological characteristics and prognosis of colorectal mucinous adenocarcinoma and nonmucinous adenocarcinoma: a surveillance, epidemiology, and end results (SEER) population-based study.

Zhi-Ping Li, Xin-Yi Liu, Xiao-Ming Kao, Yi-Tian Chen, Si-Qi Han, Meng-Xi Huang, Chao Liu, Xin-Yi Tang, Yan-Yan Chen, Dan Xiang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Rethinking mucinous colorectal adenocarcinoma classification: evidence from histopathology and RAS mutations.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Zhi-Ping LiDepartment of Medical Oncology, Jinling Hospital, The First School of Clinical Medicine, Southern Medical University, Nanjing 210002, China.
Xin-Yi LiuDepartment of Radiology, Shenzhen Children's Hospital, Shantou University Medical College, Shenzhen 518000, China.
Xiao-Ming KaoDepartment of General Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China.
Yi-Tian ChenDepartment of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China.
Si-Qi HanDepartment of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China.
Meng-Xi HuangDepartment of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China.
Chao LiuDepartment of Medical Oncology, Jinling Hospital, Nanjing Clinical School of Nanjing Medical University, Nanjing 210002, China.
Xin-Yi TangDepartment of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China.
Yan-Yan ChenDepartment of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China.
Dan XiangDepartment of Medical Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China.
Ya-Di HuangDepartment of Medical Oncology, Jinling Hospital, The First School of Clinical Medicine, Southern Medical University, Nanjing 210002, China.
Zeng-Jie LeiDepartment of Medical Oncology, Jinling Hospital, The First School of Clinical Medicine, Southern Medical University, Nanjing 210002, China.
Xiao-Yuan ChuDepartment of Medical Oncology, Jinling Hospital, The First School of Clinical Medicine, Southern Medical University, Nanjing 210002, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMucinous adenocarcinoma (MC) is a rare histological subtype of colorectal adenocarcinoma. Previous studies investigating the prognosis of MC have conflicting results and the proper treatment of MC remains unclear.

methodsThis retrospective study presents the clinicopathological characteristics and prognosis of MC. This cohort study collected data from April 1 through August 01, 2018. This study used data on 107,735 patients with nonmucinous adenocarcinoma (NMC) and 9,494 with MC between 2009 and 2013 from the Surveillance, Epidemiology, and End Results program (SEER). Clinicopathological features were analyzed by chi-square test and survival curves by the Kaplan-Meier method. We used propensity score matching (PSM) to account for potential bias. Logistic regression and Cox proportional hazards models were used to compare and calculate adjusted risks of MC death.

resultsMC was more frequent in patients with older age, large tumor size and moderate tumor grade compared with NMC (P<0.001). Five-year survival was lower for MC patients than NMC patients (P<0.001). Older age, later tumor node metastasis (TNM) stage and multiple tumors indicated a poorer prognosis while surgery gave better survival outcomes [hazard ratio (HR) =0.38; 95% confidence interval (CI), 0.33 to 0.44; P<0.001]. Younger age, left-side colon location and early disease stage were associated with better survival after surgery (P<0.001).

conclusionsAge, TNM stage, tumor number and treatment were indicators of prognosis and surgery gave better survival for MC patients compared with those without surgery. Our study contributes to their clinical treatment.

Indexed as

Colorectal cancer (CRC)mucinous adenocarcinoma (MC)prognosis factortreatments

Identifiers

PMID32309352
PMCPMC7154470

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.